Intropic agents in the treatment of heart failure: Despair or hope?

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cardiovascular Drugs and Therapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00053027PMID 9110113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside

  2007cited by this paper
• Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure

  2005cited by this paper
• Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure

  2005cited by this paper
• Serotonin and acute cardiovascular disorders

  2004cited by this paper
• Digoxin—A redundant drug in congestive cardiac failure

  2004cited by this paper
• Tumour necrosis factor is expressed in cardiac tissues of patients with heart failure.

  1996cited by this paper
• Role of cytokines in the syndrome of heart failure.

  1996cited by this paper
• Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.

  1996cited by this paper
• Interaction of cytotoxic T lymphocytes and guinea pig ventricular myocytes. Pharmacological modulation by blocking K+ currents in cytotoxic T lymphocytes.

  1996cited by this paper
• Immune modulation of cardiac function: a new frontier.

  1995cited by this paper
• Antibody-mediated imbalance of myocardial energy metabolism. A causal factor of cardiac failure?

  1995cited by this paper
• Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure.

  1995cited by this paper
• Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture.

  1995cited by this paper
• Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells.

  1995cited by this paper
• Scientific insights from clinical studies of converting-enzyme inhibitors in the failing heart.

  1995cited by this paper
• Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia.

  1994cited by this paper
• Therapeutic Effect of Anti‐Tumor Necrosis Factor‐α Antibody on the Murine Model of Viral Myocarditis Induced by Encephalomyocarditis Virus

  1994cited by this paper
• Mechanisms of immune-mediated myocyte injury.

  1994cited by this paper
• Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line.

  1994cited by this paper
• Increased circulating cytokines in patients with myocarditis and cardiomyopathy.

  1994cited by this paper
• Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.

  1994cited by this paper
• Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.

  1994cited by this paper
• Is cardiac failure a consequence of decreased energy reserve

  1993cited by this paper
• Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators.

  1993cited by this paper
• The development of positive inotropic agents for chronic heart failure: how have we gone astray?

  1993cited by this paper
• Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.

  1993cited by this paper
• Medical Advances in the Treatment of Congestive Heart Failure

  1993cited by this paper
• Effects of vesnarinone on morbidity and mortality in patients with heart failure

  1993cited by this paper
• Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors.

  1993cited by this paper
• Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study.

  1993cited by this paper
• Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation

  1993cited by this paper
• The epidemiology of heart failure: the Framingham Study.

  1993influential reference
• Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure.

  1992cited by this paper
• Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors.

  1992cited by this paper
• What do the newer inotropic drugs have to offer?

  1992cited by this paper
• Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.

  1992cited by this paper
• Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.

  1991cited by this paper
• Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

  1990cited by this paper
• Xamoterol in severe heart failure.

  1990cited by this paper
• Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group.

  1990cited by this paper
• A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure

  1990cited by this paper
• Influence of the Positive Inotropic Substance Pimobendan (UD‐CG 115 BS) on Contractile Economy of Guinea Pig Papillary μscles

  1989cited by this paper
• Pimobendan Increases Survival of Cardiomyopathic Hamsters

  1989cited by this paper
• Calcium-sensitivity modulation of cardiac myofibrillar proteins.

  1989cited by this paper
• A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.

  1989cited by this paper
• The Positive Inotropic Effect of Pimobendan Involves Stereospecific Increases in the Calcium Sensitivity of Cardiac Myofilaments

  1989cited by this paper
• Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings.

  1989cited by this paper
• Long-term effects of xamoterol on left ventricular diastolic function and late remodeling: a study in patients with anterior myocardial infarction and single-vessel disease.

  1988cited by this paper
• Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group.

  1988cited by this paper
• DOUBLE-BLIND PLACEBO-CONTROLLED COMPARISON OF DIGOXIN AND XAMOTEROL IN CHRONIC HEART FAILURE

  1988cited by this paper
• Sensitization of Dog and Guinea Pig Heart Myofilaments to Ca2+Activation and the Inotropic Effect of Pimobendan: Comparison With Milrinone

  1988cited by this paper
• Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group.

  1988cited by this paper
• Histologic and biochemical correlates of left ventricular chamber dynamics in man.

  1987cited by this paper
• Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart.

  1987cited by this paper
• Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.

  1987cited by this paper
• Potential deleterious effects of inotropic agents in the therapy of chronic heart failure.

  1986cited by this paper
• Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties.

  1986cited by this paper
• Cardiovascular effects of ICI 118,587, a new beta-adrenoceptor partial agonist in man.

  1986cited by this paper
• Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.

  1986cited by this paper
• Potential deleterious effects of inotropic agents in the therapy of chronic heart failure.

  1986cited by this paper
• Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.

  1985cited by this paper
• Udcg 115 and 212, 2 benzimidazo-pyridazinones with broad-spectrum antiplatelet activity

  1985cited by this paper
• Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study.

  1984cited by this paper
• Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure.

  1984cited by this paper
• Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.

  1984cited by this paper
• Effects of discontinuing maintenance digoxin therapy in patients with ischemic heart disease and congestive heart failure in sinus rhythm.

  1983cited by this paper
• Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure.

  1983cited by this paper
• Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm.

  1982cited by this paper
• Transient Depolarization and Spontaneous Voltage Fluctuations in Isolated Single Cells from Guinea Pig Ventricles: Calcium‐Mediated Membrane Potential Fluctuations

  1982cited by this paper
• Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

  1982cited by this paper
• Herpes simplex type 2 virus encephalitis presenting as psychosis.

  1982cited by this paper
• Stereological measurement of cellular and subcellular hypertrophy and hyperplasia in the papillary muscle of adult rat.

  1980cited by this paper
• Hemodynamic assessment of amrinone. A new inotropic agent.

  1978cited by this paper
• Diuretic-induced oedema.

  1975cited by this paper
• Rate of Calcium Binding and Uptake in Normal Animal and Failing Human Cardiac Muscle: MEMBRANE VESICLES (RELAXING SYSTEM) AND MITOCHONDRIA

  1969cited by this paper

• The evolutionarily conserved C-terminal peptide of troponin I is an independently configured regulatory structure to function as a myofilament Ca2+-desensitizer.

  2019cites this paper
• The Patient with Advanced Chronic Heart Failure

  2018cites this paper
• A Review on Study of Various Ionotropic Calcium Sensitizing Drugs in Congestive Heart Failure Treatment

  2014cites this paper
• Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.

  2013cites this paper
• Validation of an in vitro contractility assay using canine ventricular myocytes.

  2012cites this paper
• Chapter 61 – Management of End-Stage Heart Failure

  2011cites this paper
• Place des inotropes et des vasopresseurs dans ľinsuffisance cardiaque aiguë

  2006cites this paper
• Optimising Outcomes in End-Stage Heart Failure

  2004cites this paper
• The mechanism of the selective inotropic and hypotensive effects of triterpenoids of plant origin.

  2004cites this paper
• Inotropic therapy is unsuccessful: wrong conceptual target or wrong therapeutic tools?

  2003cites this paper
• Inotropic Agents and Immune Modulation

  2002cites this paper
• A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy.

  2002cites this paper
• The dilemma of late-stage heart failure. Rationale for chronic parenteral inotropic support.

  2001cites this paper
• Intermittent positive inotrope infusion in the management of end-stage, low-output heart failure.

  2000cites this paper
• Overall cardiac functional effect of positive inotropic drugs with differing effects on relaxation.

  2000cites this paper
• Cardiac Sodium Channels as Targets for New Inotropic Agents

  1998cites this paper